Rx Drugs Novel Care Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 42.97%
- Profit Growth -14.81%
- Ebitda -14.81%
- Net Worth -43.26%
- Total Assets -90.28%
About Rx Drugs Novel Care
Rx Drugs Novel Care Private Limited (RDNCPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 September 2019 (Five years and four months 19 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Umamaheswara Veravalli and Ramadevi Veeravalli serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24110TG2019PTC135423
- Company No.
135423
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Sep 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Rx Drugs Novel Care?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umamaheswara Veravalli  | Director | 13-Sep-2019 | Current |
| Ramadevi Veeravalli | Director | 13-Sep-2019 | Current |
Financial Performance of Rx Drugs Novel Care.
Rx Drugs Novel Care Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 42.97% increase. The company also saw a substantial fall in profitability, with a 14.81% decrease in profit. The company's net worth observed a substantial decline by a decrease of 43.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rx Drugs Novel Care?
Unlock access to Rx Drugs Novel Care's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Neorx Drugs India Private LimitedUmamaheswara Veravalli and Ramadevi Veeravalli are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rx Drugs Novel Care?
Unlock and access historical data on people associated with Rx Drugs Novel Care, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rx Drugs Novel Care, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rx Drugs Novel Care's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.